Gilad Oren is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $31K. Historical track record: 4/5 stars across 5 tracked purchases.
Profile
Oren Gilad is the President and Chief Executive Officer and a director of Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology and synthetic lethality. His SEC filings for the company (CIK 0001929300) indicate four filings through 2026-02-02 with no reported purchases or sales, reflecting a leadership role and active oversight of corporate strategy. Aprea's pipeline includes ATRN-119 (an ATR inhibitor) and APR-1051 (a WEE1 inhibitor) in clinical development.
Role
President/CEO, Director
Notability
40/100
Board memberships
Aprea Therapeutics, Inc.
Awards & honors
Leading Aprea Therapeutics' executive team and governance since assuming CEO
Oversight of clinical development programs ATRN-119 and APR-1051
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
Oren Gilad is the President and Chief Executive Officer and a director of Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology and synthetic lethality. His SEC filings for the company (CIK 0001929300) indicate four filings through 2026-02-02 with no reported purchases or sales, reflecting a leadership role and active oversight of co…
Has Gilad Oren been buying or selling stock?
Recorded transactions: 6 open-market purchases ($31K) and 0 open-market sales () across all tracked filings.
How accurate is Gilad Oren's historical track record?
Across 5 tracked purchases, Gilad Oren averaged +1246.8% avg 30-day return with a 8000% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
Where can I see all of Gilad Oren's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
